Welcome!

News Feed Item

AbbVie Announces Availability of New Advanced Parkinson's Treatment in Canada

DUODOPA improves quality of life for those with advanced stages of disease

MONTREAL, April 10, 2014 /CNW/ - AbbVie today announced that a new treatment called DUODOPA® (levodopa/carbidopa intestinal gel) is now available to Canadians with advanced Parkinson's disease. Currently, more than 100,000 Canadians live with Parkinson's – a progressive, incurable neurological disorder that can significantly affect the quality of life of patients, their families and caregivers.

DUODOPA is approved in Canada for the management of advanced Parkinson's disease in adults with severe, disabling motor fluctuations and hyper-/dyskinesia (involuntary movements) not satisfactorily controlled by combinations of available oral medicinal products for Parkinson's disease.

"A major problem that emerges over time in people with Parkinson's disease is fluctuations in their ability to move due to unreliable absorption of oral medications. This leads to inconsistent delivery of the chemical dopamine which controls movement to the brain resulting in unpredictable motor function," said Dr. Anthony Lang of the Movement Disorder Centre at Toronto Western Hospital, University Health Network, which is one of four centers of excellence in Canada to treat advanced Parkinson's patients with this new treatment. "DUODOPA is a treatment option that enables patients to regain control over their movements and balance which in turn drastically improves their quality of life."

Parkinson's disease, which involves significant loss of limb and balance control, is most commonly diagnosed at 50-60 years of age – although diagnosis can occur at a much younger age. The standard treatment for Parkinson's disease begins with oral therapies, including levodopa, which usually work well during the first years. As the disease progresses, oral therapies no longer provide satisfactory control over severe motor fluctuations and dyskinesia. Now with DUODOPA there is a new option.

"I am a writer and I could not write. I would have very painful tremors in my right hand and rigidity on my entire left side," said Doug Curtis, a playwright who has been living with Parkinson's disease for 10 years. He is one of the first Parkinson's patients in North America to receive DUODOPA.  "Parkinson's took away my ability to express myself. But now I can write again. The tempo of my life has returned.  I now have the confidence to take on Parkinson's head on."

"My husband was progressively getting worse as he moved into the advanced stages of the disease. Simple daily tasks became a challenge and he became dependent on me," said Heather Moore, Doug's wife and caregiver. "Today, I see Doug's condition improving and because of this progress my family has regained a sense of normalcy in our lives."

About Parkinson's Disease (PD)
PD is a progressive neurological disease that affects approximately 6.3 million people, making it the second most common degenerative neurological disorder worldwide1,2.

The severity of PD and how it impacts an individual varies from person to person. The symptoms are predominantly characterized by problems with body movements, called motor symptoms3. These symptoms include tremor, or shaking (often in the hand, arm or leg); rigidity, or stiffness in muscles; slowness of movement, and poor balance and instability3,4. As the disease progresses, these symptoms can worsen to the point where a person becomes dependent on others to perform even basic activities, such as help getting out of a chair and turning over in bed3,5.

Currently there is no cure for PD and symptoms may gradually continue to worsen in the years following diagnosis6. The goal of treatment for PD is to manage motor symptoms, which reduces tremor, rigidity and slowness of movement1.

About DUODOPA

  • DUODOPA® is indicated for treatment of advanced levodopa-responsive PD with severe motor fluctuations and hyper-/dyskinesia when available combinations of PD medicinal products have not given satisfactory results7.
  • DUODOPA® provides an effective treatment for people with PD enabling more "ON" time in comparison to oral levodopa7.
  • DUODOPA® was approved in recognition of a high unmet need for effective therapies and no satisfactory alternatives8.
  • DUODOPA® is contraindicated in patients with narrow-angle glaucoma, severe liver and renal insufficiency, severe heart failure, severe cardiac arrhythmia, suspicious, undiagnosed skin lesions or a history of melanoma, acute stroke and in patients taking non-selective MAO inhibitors and selective MAO type A inhibitors7.

About AbbVie
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs approximately 25,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com and www.abbvie.ca. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

________________________________________
1
Mobin A. A comparative analysis of how Michael J. Fox and Muhammad Ali changed the world's views on Parkinson's disease. J Parkinsonism Restless Legs Syndrome 2011;1:1–4.
2 de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525–35.
3 Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368–376.
4 Clarke CE. Parkinson's disease. BMJ 2007;335:441–445.
5 ICD9 Data.com. Parkinson's disease 332. Available at: http://www.icd9data.com/2013/Volume1/320-389/330-337/332/default.htm (Last accessed December 2013).
6 Denyer R, Douglas MR. Gene therapy for Parkinson's disease. Parkinsons Dis 2012;2012:757305.
7 AbbVie Limited. Summary of product characteristics: Duodopa intestinal gel, October 2013. Available at: http://www.medicines.org.uk/emc/medicine/20786/SPC/Duodopa+intestinal+gel/ (Last accessed December 2013).
8 European Medicines Agency. Public summary of opinion on orphan designation: levodopa/carbidopa (gastroenteral use) for the treatment of advanced idiopathic Parkinson's disease with severe motor fluctuations and not responding to oral treatment. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500006499.pdf (Last accessed December 2013).

SOURCE AbbVie

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Numerex Corp, a leading provider of managed enterprise solutions enabling the Internet of Things (IoT), will exhibit at the 19th International Cloud Expo | @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Numerex Corp. (NASDAQ:NMRX) is a leading provider of managed enterprise solutions enabling the Internet of Things (IoT). The Company's solutions produce new revenue streams or create operating...
If you’re responsible for an application that depends on the data or functionality of various IoT endpoints – either sensors or devices – your brand reputation depends on the security, reliability, and compliance of its many integrated parts. If your application fails to deliver the expected business results, your customers and partners won't care if that failure stems from the code you developed or from a component that you integrated. What can you do to ensure that the endpoints work as expect...
WebRTC adoption has generated a wave of creative uses of communications and collaboration through websites, sales apps, customer care and business applications. As WebRTC has become more mainstream it has evolved to use cases beyond the original peer-to-peer case, which has led to a repeating requirement for interoperability with existing infrastructures. In his session at @ThingsExpo, Graham Holt, Executive Vice President of Daitan Group, will cover implementation examples that have enabled ea...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace.
SYS-CON Events announced today that Tintri Inc., a leading producer of VM-aware storage (VAS) for virtualization and cloud environments, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Tintri VM-aware storage is the simplest for virtualized applications and cloud. Organizations including GE, Toyota, United Healthcare, NASA and 6 of the Fortune 15 have said “No to LUNs.” With Tintri they mana...
Major trends and emerging technologies – from virtual reality and IoT, to Big Data and algorithms – are helping organizations innovate in the digital era. However, to create real business value, IT must think beyond the ‘what’ of digital transformation to the ‘how’ to harness emerging trends, innovation and disruption. Architecture is the key that underpins and ties all these efforts together. In the digital age, it’s important to invest in architecture, extend the enterprise footprint to the cl...
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Cognitive Computing is becoming the foundation for a new generation of solutions that have the potential to transform business. Unlike traditional approaches to building solutions, a cognitive computing approach allows the data to help determine the way applications are designed. This contrasts with conventional software development that begins with defining logic based on the current way a business operates. In her session at 18th Cloud Expo, Judith S. Hurwitz, President and CEO of Hurwitz & ...
In his keynote at 18th Cloud Expo, Andrew Keys, Co-Founder of ConsenSys Enterprise, provided an overview of the evolution of the Internet and the Database and the future of their combination – the Blockchain. Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life sett...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
SYS-CON Events announced today that ReadyTalk, a leading provider of online conferencing and webinar services, has been named Vendor Presentation Sponsor at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. ReadyTalk delivers audio and web conferencing services that inspire collaboration and enable the Future of Work for today’s increasingly digital and mobile workforce. By combining intuitive, innovative tec...
SYS-CON Events announced today that Secure Channels will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. The bedrock of Secure Channels Technology is a uniquely modified and enhanced process based on superencipherment. Superencipherment is the process of encrypting an already encrypted message one or more times, either using the same or a different algorithm.
Vidyo, Inc., has joined the Alliance for Open Media. The Alliance for Open Media is a non-profit organization working to define and develop media technologies that address the need for an open standard for video compression and delivery over the web. As a member of the Alliance, Vidyo will collaborate with industry leaders in pursuit of an open and royalty-free AOMedia Video codec, AV1. Vidyo’s contributions to the organization will bring to bear its long history of expertise in codec technolo...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...